Research programme: autoimmune disease therapeutics - OPKO Health
Latest Information Update: 16 Jul 2016
At a glance
- Originator OPKO Health
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pemphigus; Type 1 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pemphigus in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA
- 17 Oct 2011 Preclinical trials in Pemphigus in USA (unspecified route)